Australia's largest stock trading and investment forum Australia's #1 stock forum

BLT

Click for more information

0.00%

2.6¢ benitec biopharma limited

Ann: HEPATITIS C TRIAL UPDATE, page-28

First 28 Last

Share
Profile

Follow
Risiko

927 Posts.

16

29/04/15

22:03

Post #: 15184403
Share

Originally posted by phillip_k ↑

I can understand the patient by patient commentary being ongoing to be a bit of a pain. Having said that BLT had no other choice as they created expectations and ten had to explain delays. I can see why they don't want to keep on doing this.

BLT has however a continuous disclosure obligation. At a minimum there should: eg,
1. Results of Cohort 2 (in aggregate, not patient by patient).
2. The tick of the DSMB to continue.
3. A statement that all patients in Cohort 3 have been dosed when it occurs.
4. Results of Cohort 3.
5.6,, 7 etc...As for Cohorts 4 and 5.

Does BLT management think they can wait potentially until the end of Cohort 5, with the catchphrase "material" being the ultimate tool in flexibility of reporting?
This is a structured trial, which has been marketed as such, and BLT should be obligated to report against milestones along the lines of that structure.

Expand

Exactly!

BLT Price at posting: 78.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Emerald & Azure score Digger & Dealer awards

KCC

Kincora partners with Woomera to advance Mongolian copper-gold play

Bitcoin: Current State of Play & Where to Next | Swyftx

BAS

Bass Oil officially cites mid-October as final date for Kiwi-1 production test – a well first drilled 21 years ago

PAM

Pan Asia nearly triples anomalous zone for lithium at large prospect in Thailand

There are more pages in this discussion • 6 more messages in this thread...

First 28 Last

Add BLT (ASX) to my watchlist